I enjoy your cut to the chase observations, at least in the
I enjoy your cut to the chase observations, at least in the medical community we add to your analogy everyone has one but we don't want to hear from them....
I probably should not have introduced that link as "an opinion piece" he has hard data on mortality studies and reviews the specific studies only mention very few become statically significance especially when Type 1 errors are factored in (combined false positive and false negative) and thereby the rejection of the null hypothesis. He does not state they are to be abandoned altogether, they often shed light on the SECONDARY endpoint. I bring this up in the event CD12 does not achieve overwhelming data, that DOES not mean that it does not decrease mortality.
The article simply states that if all cause mortality is not significant, drill down on secondary endpoints, the drug should not be abandoned before that analysis. Of course reproducibility in non-company sponsored trials is the gold standard to create "Evidence Based Medicine" which will market the drug to providers without spending a dime.
All positive news for us, obviously time will tell.
I also think this applies to us: Oncoimmune CD24FC trial was completed in September with very promising results. They stated they would wait for submitting to the FDA until peer reviewed publications were made. Then they were bought by Merck still not approved, yet the government signed a $350,000,000 contract. Still not approved. Merck announced a major capital investment in repurposing of their manufacturing platform. I surmise the FDA is waiting for evidence of a reliable supply chain.
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...
Continue Reading
Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...
Continue Reading
Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...
Continue Reading
An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...
Continue Reading
Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...
Continue Reading
Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...
Continue Reading
AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...
Continue Reading
A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...
Continue Reading
Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...
Continue Reading
They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...
Continue Reading
Top 5 Most Recently Viewed Articles
Floor & Decor Expands to Pensacola with New Store Launch Floor & Decor (NYSE: FND), a leader in the hard-surface flooring retail market, has proudly inaugurated its first store in Pensacola. This new facility, located at 7171 North Davis Highway, is an important milestone for the company as it marks their continued expansion throughout Florida. With a dedicated team of...
Continue Reading
AB Science SA, a pharmaceutical innovator known for developing targeted therapies, confirmed a slight delay in its half-year financial report for 2024. The company intended to release the figures by September 30 but pushed the date back to October 7. This shift is all about giving auditors more time to ensure accuracy and compliance, but it’s also a red flag for traders...
Continue Reading
Endava plc Investors May Face Legal Challenges With recent developments in the investment world, many investors must be aware of the class action lawsuit pertaining to Endava plc, known for its digital transformation services. This lawsuit is intended for those who have experienced financial losses due to alleged misrepresentations by the company. Class Action Lawsuit...
Continue Reading
Innovative Enhancements in Prime Wheelchair Seating Solution The latest enhancements to the Prime wheelchair seating solution by Collins Aerospace, an RTX (NYSE: RTX) business, aim to provide a dignified travel experience specifically designed for electric wheelchair users. These improvements were showcased at a prominent aerospace expo recently, focusing on combining...
Continue Reading
Celebration of Resourcefulness in Utilities Frost & Sullivan proudly acknowledges the remarkable achievements of Greenville Water and Alectra Utilities by presenting them the prestigious Excellence in Resourcefulness Awards. This recognition took place during Itron Inspire 2024, which celebrates innovative advancements in energy and water services. About Alectra Utilities...
Continue Reading